GSE234647 1 V 3 REGORAFENIB HUMAN UP (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE234647 1 V 3 REGORAFENIB HUMAN UP.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE234647 1 V 3 REGORAFENIB HUMAN UP.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE234647 1 V 3 REGORAFENIB HUMAN UP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE234647 1 V 3 REGORAFENIB HUMAN UP.

Results found

Linked to

 

Label

Description

 

Gene

H4 clustered histone 15

Gene

MSL complex subunit 3B

Gene

ribosomal protein SA 2

Gene

cytokine receptor like factor 2

Gene

CENPS-CORT readthrough

Gene

tandem C2 domains, nuclear

Gene

G-patch domain and KOW motifs

Gene

fibronectin type III and ankyrin repeat domains 1

Gene

leucine rich repeat and coiled-coil centrosomal protein 1

Gene

heterogeneous nuclear ribonucleoprotein L like

  • Gene

    H4 clustered histone 15


  • Gene

    MSL complex subunit 3B


  • Gene

    ribosomal protein SA 2


  • Gene

    cytokine receptor like factor 2


  • Gene

    CENPS-CORT readthrough


  • Gene

    tandem C2 domains, nuclear


  • Gene

    G-patch domain and KOW motifs


  • Gene

    fibronectin type III and ankyrin repeat domains 1


  • Gene

    leucine rich repeat and coiled-coil centrosomal protein 1


  • Gene

    heterogeneous nuclear ribonucleoprotein L like

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.